艾帕洛利单抗托沃瑞利单抗(Iparomlimab/Tuvonralimab) - 药物靶点：CTLA4 x PD-1_在研适应症：转移性宫颈癌，复发性宫颈癌，晚期肝细胞癌_专利_临床

概要

基本信息

药物类型

单克隆抗体

别名

Anti-PD-1/CTLA-4 MabPair、Tuvonralimab/Iparomlimab、艾帕洛利托沃瑞利单抗

+ [4]

靶点

CTLA4 x PD-1

作用机制

CTLA4抑制剂(细胞毒性T淋巴细胞相关抗原4抑制剂)、PD-1抑制剂(细胞程序性死亡-1抑制剂)

治疗领域

肿瘤泌尿生殖系统疾病消化系统疾病+ [4]

在研适应症

转移性宫颈癌复发性宫颈癌晚期肝细胞癌+ [11]

非在研适应症-

原研机构

齐鲁制药有限公司

在研机构

齐鲁制药有限公司

非在研机构-

最高研发阶段批准上市

首次获批日期

中国 (2024-09-26),

转移性宫颈癌复发性宫颈癌

最高研发阶段(中国)批准上市

特殊审评附条件批准 (中国)

登录后查看时间轴

序列信息

Sequence Code 2657CDR1-H

Sequence Code 113542CDR2-L

Sequence Code 13507594CDR3-H

Sequence Code 315604171CDR1-L

Sequence Code 315604182VH

Sequence Code 315604184VL

Sequence Code 315604185CDR3-L

Sequence Code 1038074856CDR2-H

关联

34

项与艾帕洛利单抗托沃瑞利单抗相关的临床试验

NCT06509971 / Not yet recruiting临床2期IIT

A Study of QL1706 (an Anti-PD-1/CTLA-4 Combined Antibody) Combined With Albumin-bound Paclitaxel and Bevacizumab in the Treatment of Platinum-resistant Recurrent Ovarian Cancer

* Major objectives To evaluate the efficacy of QL1706 combined with albumin-binding paclitaxel and bevacizumab in the treatment of platinum-resistant recurrent ovarian cancer.
* Secondary Purpose To evaluate the safety of QL1706 in combination with albumin-binding paclitaxel and bevacizumab in the treatment of platinum-resistant recurrent ovarian cancer.
Exploratory analysis of the association between the efficacy of the combination regimen and biomarkers.

开始日期2024-07-01

申办/合作机构

四川大学华西第二医院

NCT06446388 / Not yet recruiting临床2期

A Phase II Clinical Study to Evaluate the Efficacy and Safety of QLS31905 and/or QL1706 Combination Chemotherapy for the Treatment of CLDN18.2-Positive Advanced Malignant Solid Tumors

This study aims to evaluate the efficacy and safety of QLS31905 and/or QL1706 plus chemotherapy in patients with Claudin18.2-positive advanced solid tumors.

开始日期2024-06-30

申办/合作机构

齐鲁制药有限公司

NCT06404736 / Not yet recruiting临床2期IIT

A Phase II Study of Neoadjuvant QL1706 Plus Chemotherapy in Participants With High-Risk TNBC Early-Stage Breast Cancer (QUEEN-Dream)

This study will look at the efficacy and safety of QL1706 plus albumin-bound paclitaxel and carboplatin in a neoadjuvant setting, in high-risk, TNBC early breast cancer.

开始日期2024-05-07

申办/合作机构

复旦大学

100 项与艾帕洛利单抗托沃瑞利单抗相关的临床结果

登录后查看更多信息

100 项与艾帕洛利单抗托沃瑞利单抗相关的转化医学

登录后查看更多信息

100 项与艾帕洛利单抗托沃瑞利单抗相关的专利（医药）

登录后查看更多信息

5

项与艾帕洛利单抗托沃瑞利单抗相关的文献（医药）

2023-05-08·Journal of hematology & oncology

First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors.

Article

作者: Yan, Wei ; Zhu, Dongyuan ; Qu, Shenhong ; Zhang, Yiping ; Huang, Xian ; Yang, Yingying ; Zang, Aimin ; Zhang, Li ; Peng, Yufeng ; Yu, Zhuang ; Liang, Jin ; Hao, Yanrong ; Liu, Zhi ; Xue, Shilin ; Chen, Junmin ; Chen, Chuanben ; Feng, Weineng ; Liu, Baorui ; Ba, Yi ; Zhao, Yuanyuan ; Su, Wuyun ; Qu, Song ; Chen, Zhendong ; Fanslow, Bill ; Li, Qingshan ; Jin, Chuan ; Yang, Guihong ; Ma, Yuxiang ; Liu, Xianling ; Ouyang, Weiwei ; Zhang, Guoping ; Li, Yong ; He, Jianbo ; Wang, Xiangcai ; Cheng, Ying ; Kang, Xiaoyan ; Yang, Mengxiang ; Zhao, Hongyun

BACKGROUND:

QL1706 (PSB205) is a single bifunctional MabPair (a novel technical platform) product consisting of two engineered monoclonal antibodies (anti-PD-1 IgG4 and anti-CTLA-4 IgG1), with a shorter elimination half-life (t_1/2) for CTLA-4. We report results from a phase I/Ib study of QL1706 in patients with advanced solid tumors who failed standard therapies.

METHODS:

In the phase I study, QL1706 was administered intravenously once every 3 weeks at one of five doses ranging from 0.3 to 10 mg/kg, and the maximum tolerated dose, recommended phase 2 dose (RP2D), safety, pharmacokinetics (PK), and pharmacodynamics (PD) of QL1706 were investigated. In the phase Ib study, QL1706 was administered at the RP2D intravenously every 3 weeks, and the preliminary efficacies in non-small cell lung cancer (NSCLC), nasopharyngeal carcinoma (NPC), cervical cancer (CC), and other solid tumors were evaluated.

RESULTS:

Between March 2020 and July 2021, 518 patients with advanced solid tumors were enrolled (phase I, n = 99; phase Ib, n = 419). For all patients, the three most common treatment-related adverse events (TRAEs) were rash (19.7%), hypothyroidism (13.5%), and pruritus (13.3%). The TRAEs and immune-related adverse events (irAEs) of grade ≥ 3 occurred in 16.0% and 8.1% of patients, respectively. In phase I, 2 of 6 patients in the 10mg/kg group experienced dose-limiting toxicities (DLTs) (grade 3 thrombocytopenia and grade 4 immune-mediated nephritis), so the maximum tolerated dose (MTD) was reached at 10 mg/kg. The RP2D was determined to be 5 mg/kg based on comprehensive analysis of tolerability, PK/PD, and efficacy. For all patients who received QL1706 at the RP2D, the objective response rate (ORR) and median duration of response were 16.9% (79/468) and 11.7 months (8.3-not reached [NR]), respectively; and the ORRs were 14.0% (17/121) in NSCLC, 24.5% (27/110) in NPC, 27.3% (15/55) in CC, 7.4% (2/27) in colorectal cancer, 23.1% (6/26) in small cell lung cancer. For immunotherapy-naive patients, QL1706 exhibited promising antitumor activities, especially in NSCLC, NPC, and CC, with ORRs of 24.2%, 38.7%, and 28.3%, respectively.

CONCLUSIONS:

QL1706 was well tolerated and demonstrated promising antitumor activity in solid tumors, especially in NSCLC, NPC, and CC patients. It is currently being evaluated in randomized phase II (NCT05576272, NCT05179317) and phase III (NCT05446883, NCT05487391) trials. Trial Registration ClinicalTrials.gov Identifier: NCT04296994 and NCT05171790.

2023-01-01·La Revue de medecine interne

Immune checkpoint inhibitors-induced systemic capillary leak syndrome: A report of two cases

Article

作者: Petitdemange, A ; Dimitrov, Y ; Béguin, L

INTRODUCTION:

The occurrence of systemic capillary leak syndrome under immune checkpoint inhibitors has seldom been reported in the literature.

OBSERVATION:

We report two cases of systemic capillary leak syndrome that occurred with nivolumab (anti-PD-1 antibody) for one, and with an anti-PD-1/CTLA-4 bi-specific antibody for the other. Patients presented with anasarca, hypoalbuminemia, acute kidney injury and, in one case, circulatory collapse. Immune checkpoint inhibitor causality was retained in the lack of evidence for other causes of secondary capillary leak syndrome or for an idiopathic form. The symptoms resolved after a few days of supportive measures (associated with glucocorticoids in one case).

DISCUSSION:

A high index of suspicion is required for the diagnosis of immune checkpoint inhibitors-induced systemic capillary leak syndrome because its presentation may differ from that of the idiopathic form. Activated CD8⁺ T-cells play a prominent role in the occurrence of immune checkpoint inhibitors-induced capillary leakage via their cytolytic action on the vascular endothelium. Treatment relies on supportive measures and discontinuation of the immune checkpoint inhibitor while the place of immunomodulatory drugs remains to be defined.

2020-01-01·Journal of neuro-oncology2区 · 医学

The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study

2区 · 医学

Article

作者: Martins, Filipe ; Levivier, Marc ; Bettini, Adrienne ; Cuendet, Michel A ; Michielin, Olivier ; Schiappacasse, Luis ; Homicsko, Krisztian ; Berthod, Gregoire ; Wicky, Alexandre ; Aedo-Lopez, Veronica ; Bourhis, Jean ; Tuleasca, Constantin ; Gautron Moura, Bianca ; Gérard, Camille L

BACKGROUND:

Evidence pointing to a synergistic effect of stereotactic radiosurgery (SRS) with concurrent immunotherapy or targeted therapy in patients with melanoma brain metastases (BM) is increasing. We aimed to analyze the effect on overall survival (OS) of immune checkpoint inhibitors (ICI) or BRAF/MEK inhibitors initiated during the 9 weeks before or after SRS. We also evaluated the prognostic value of patients' and disease characteristics as predictors of OS in patients treated with SRS.

METHODS:

We identified patients with BM from cutaneous or unknown primary origin melanoma treated with SRS between 2011 and 2018.

RESULTS:

We included 84 patients. The median OS was 12 months (95% CI 9-20 months). The median follow-up was 30 months (95% CI 28-49). Twenty-eight patients with newly diagnosed BM initiated anti-PD-1 +/-CTLA-4 therapy (n = 18), ipilimumab monotherapy (n = 10) or BRAF+/- MEK inhibitors (n = 11), during the 9 weeks before or after SRS. Patients who received anti-PD-1 +/-CTLA-4 mAb showed an improved survival in comparison to ipilimumab monotherapy (OS 24 vs. 7.5 months; HR 0.32, 95% 0.12-0.83, p = 0.02) and BRAF +/-MEK inhibitors (OS 24 vs. 7 months, respectively; HR 0.11, 95% 0.04-0.34, p = 0.0001). This benefit remained significant when compared to the subgroup of patients treated with dual BRAF/MEK inhibition (BMi) (n = 5). In a multivariate Cox regression analysis an age > 65, synchronous BM, > 2 metastatic sites, > 4 BM, and an ECOG > 1 were correlated with poorer prognosis. A treatment with anti-PD-1+/-CTLA-4 mAbs within 9 weeks of SRS was associated with better outcomes. The presence of serum lactate dehydrogenase (LDH) levels ≥ 2xULN at BM diagnosis was associated with lower OS (HR 1.60, 95% CI 1.03-2.50; p = 0.04).

CONCLUSIONS:

The concurrent administration of anti-PD-1+/-CTLA-4 mAbs with SRS was associated with improved survival in melanoma patients with newly diagnosed BM. In addition to CNS tumor burden, the extension of systemic disease retains its prognostic value in patients treated with SRS. Elevated serum LDH levels are predictors of poor outcome in these patients.

146

项与艾帕洛利单抗托沃瑞利单抗相关的新闻（医药）

2024-11-03

·米内网

10月10个品种获批新适应症，12个品种首家过评，这4家企业仿制申报最多

摘要 abstract 2024年10月，4个1类新药、10个改良型新药申报上市；241个品种按新分类仿制申请申报，其中39个品种暂无国内仿制获批，富马酸伏诺拉生片有7家企业提交仿制申请，有4家企业仿制申报品种数最多，各有4个；28个存量品种有企业申报一致性评价，其中1个品种为首次申报；5个1类新药、1个新复方制剂获批上市，10个品种获批新适应症；12个品种首家过评，其中5个为首仿。创新药品种申报情况 2024年10月，133个创新药品种（药品注册分类为“1”的品种）获CDE承办。4个品种申请上市：Aficamten片(Cytokinetics)、SHR2554片(江苏恒瑞医药)、康太替尼颗粒(首药控股(北京))、注射用芦康沙妥珠单抗(四川科伦博泰生物医药)。2024年10月创新药上市申请承办情况2024年10月创新药临床申请承办情况改良型新药品种申报情况 2024年10月，50个改良型新药品种获CDE承办。埃万妥单抗注射液(皮下注射)(强生)以及利拉鲁肽注射液(深圳翰宇药业)为剂型优化或新给药途径，海曲泊帕乙醇胺片(江苏恒瑞医药)、甲磺酸兰泽替尼片(强生)、甲磺酸仑伐替尼胶囊(卫材)、米吉珠单抗注射液(礼来)、米吉珠单抗注射液(皮下注射)(礼来)、盐酸安罗替尼胶囊(正大天晴药业集团)、注射用泰它西普(荣昌生物制药(烟台))、注射用维迪西妥单抗(荣昌生物制药(烟台))8个品种为新适应症上市申请。2024年10月改良型新药上市申请承办情况2024年10月改良型新药临床申请承办情况新分类仿制药品种申报情况 2024年10月，241个品种仿制申请获CDE承办，其中39个品种目前暂无国内仿制药获批。富马酸伏诺拉生片的仿制申请企业最多，有7家：安徽宏业药业、成都秦润医药科技、海南葫芦娃药业集团、江苏中邦制药、山东诚创蓝海医药科技、山东齐都药业、天地恒一制药。此外，山东齐都药业、山东百诺医药、辰欣药业、北京福元医药等企业的申报品种数最多，均有4个。2024年10月新分类仿制药品种申报情况存量品种一致性评价申报情况 2024年10月，28个品种的一致性评价补充申请获CDE承办。多索茶碱片首次有企业按补充申请申报。2024年10月存量品种一致性评价申报情况获批情况 2024年10月有5款1类新药首次获批上市：艾帕洛利托沃瑞利单抗注射液(齐鲁制药)、昂戈瑞西单抗注射液(上海君实生物医药科技)、夫那奇珠单抗注射液(苏州盛迪亚生物医药)、甲磺酸普雷福韦片(西安葛蓝新通制药)、伊努西单抗注射液(康融东方(广东)医药)，尼拉帕利阿比特龙片(强生)为新复方制剂。此外，还有10个品种获批新适应症。139个品种按新分类仿制申请获批并视同过评，54个品种按存量品种一致性评价补充申请过评。有12个品种首家过评，其中，波生坦片(北京四环科宝制药)、复方聚乙二醇(3350)电解质维C散(舒泰神(北京)生物制药)、来特莫韦注射液(南京正大天晴制药)、利奥西呱片(齐鲁制药)、美沙拉秦肠溶缓释颗粒(江苏安必生制药)5个品种为国内首仿。2024年10月主要注册类型品种获批情况数据来源：米内网中国申报进度数据库（MED）、CDE、NMPA；相关统计字段按药品名称统计，申报企业数按主申报企业统计，时间截至2024年10月31日；获批品种按NMPA发布时间统计；药物作用靶点以及适应症整理自公开资料。本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com 稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 【分享、点赞、在看】点一点不失联哦

一致性评价上市批准

2024-10-26

·ioncology

ESMO ASIA 2024丨一文了解重要的妇科肿瘤口头报告

点击蓝字关注我们 2024年欧洲肿瘤内科学会亚洲年会（ESMO Asia Congress 2024）将于当地时间12月6日~8日在新加坡召开。ESMO ASIA是亚太地区讨论肿瘤学领域重磅突破的领先平台，近日在官方网站正式公布本次大会的摘要题目及作者信息。肿瘤瞭望小编带您先睹为快，一览妇科肿瘤领域入选优选口头报告（Proffered Paper）和微型口头报告（Mini Oral）的临床研究。 1 口头报告（Proffered Paper）摘要号：372O 英文标题：Balstilimab (bal) alone or with zalifrelimab (zal) treatment for cervical cancer: an open-label, non-comparative, randomised, phase 2 trial 中文标题：Balstilimab单药或Balstilimab+zalifrelimab治疗宫颈癌：一项开放标签、非对照、随机、II期试验讲者：吴令英(中国医学科学院肿瘤医院) 摘要号：373O 英文标题：First-line iparomlimab and tuvonralimab (QL1706) + chemotherapy (chemo) ± bevacizumab (BEV) for recurrent or metastatic cervical cancer (r/mCC): Updated results of the phase II DUBHE-C-204 study 中文标题：艾帕洛利托沃瑞利单抗(Iparomlimab/Tuvonralimab)+化疗±贝伐珠单抗一线治疗复发性或转移性宫颈癌：II期DUBHE-C-204研究的最新结果讲者：王丹波(辽宁省肿瘤医院) 摘要号：374O 英文标题：The burden and trends of gynecological cancers in Asia from 1980 to 2021: A systematic analysis for the Global Burden of Disease Study 2021 中文标题：1980~2021年亚洲妇科癌症负担及趋势：2021年全球疾病负担研究的系统分析讲者：Run Miao (安徽医科大学) 摘要号：375O 英文标题：DIsease burden and treatment pattern of Recurrent or advanced Endometrial Cancer in Korea: a naTIONwide database (DIRECTION) study 中文标题：韩国复发性或晚期子宫内膜癌的疾病负担和治疗模式：全国数据库DIRECTION研究讲者：Hyun-woong Cho (韩国首尔) 2 微型口头报告（Mini Oral）摘要号：376MO 英文标题：The impact of crossover to surgery in the no-surgery group on the survival: a post-hoc analysis of the SOC-1 trial 中文标题：非手术组患者交叉接受手术对生存的影响：SOC-1试验的事后分析讲者：Lina Shen (中国上海) 摘要号：377MO 英文标题：Lymph node dissection before initial treatment for locally advanced cervical cancer: a systematic review and meta-analysis 中文标题：局部晚期宫颈癌初始治疗前的淋巴结清扫：系统评价与荟萃分析讲者：He Zhang (中国医学科学院肿瘤医院) 摘要号：378MO 英文标题：Efficacy and Safety of Disitamab Vedotin in Treatment of HER2 Expressed Advanced or Recurrent Gynecological Cancers 中文标题：Disitamab Vedotin治疗HER2表达的晚期或复发性妇科癌症的疗效和安全性讲者：王东雁(中山大学孙逸仙纪念医院) 摘要号：379MO 英文标题：Homologous recombination deficiency testing in Vietnamese patients with ovarian cancer 中文标题：越南卵巢癌患者同源重组缺陷检测讲者：Nam H. Tran (越南胡志明市) 摘要号：380MO 英文标题：Role of Therapy in the Development of Second Primary Malignancies in Ovarian Cancer Survivors: A SEER Database Analysis 中文标题：治疗在卵巢癌幸存者中对于发生第二原发性恶性肿瘤的作用：SEER数据库分析讲者：Alhareth Alhusban (约旦安曼) 摘要号：381MO 英文标题：Progression Free Survival and Overall Survival in Platinum-Based Chemotherapy Alone versus Immune Checkpoint Inhibitor (ICI)-Platinum-Based Chemotherapy Combination in First Line Treatment for Advanced, Metastatic or Recurrent Endometrial Adenocarcinoma: A Meta-Analysis 中文标题：晚期、转移性或复发性子宫内膜腺癌一线治疗中单独使用铂类化疗vs免疫检查点抑制剂(ICI)+铂类化疗的无进展生存期和总生存期：一项荟萃分析讲者：Maria Carmela Y. Vistal (菲律宾奎松城) （来源：《肿瘤瞭望》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

临床结果抗体药物偶联物临床研究

2024-10-23

·米内网

【瞩目】年年暴涨的明星药，齐鲁制药拿下国产第二家

精彩内容近日，齐鲁制药的克立硼罗软膏顺利获批，成为国产第二家。克立硼罗软膏是皮肤病用药潜力产品，上市以来年年暴涨，在中国三大终端六大市场（统计范围见文末）的销售额已累计超过3亿元。近两年，齐鲁制药的皮肤病用药快速增长，潜力可期。图1：齐鲁制药最新获批的产品来源：国家药监局官网据悉，克立硼罗软膏适用于2岁及以上轻度至中度特应性皮炎患者的局部外用治疗，米内网数据显示，原研企业Anacor在2020年获批进入中国市场，2021年首次进入医保谈判目录，2024年9月南京万融健诚医药科技拿下该产品的国内首仿，齐鲁制药为该产品国产第二家获批企业。图2：已上市的克立硼罗软膏来源：米内网中国上市药品（MID）数据库图3：克立硼罗软膏的销售情况（单位：万元）来源：米内网格局数据库在中国三大终端六大市场，原研的克立硼罗软膏销售额快速攀升，2021-2024上半年分别增长了1989.09%、261.52%、82.20%、19.31%，截至今年上半年该产品的销售额累计超过3亿元。表1：齐鲁制药部分已上市的皮肤病用药销售增长情况来源：米内网格局数据库在中国三大终端六大市场，齐鲁制药多个皮肤病用药近两年保持快速增长态势，盐酸特比萘芬乳膏、盐酸特比萘芬喷雾剂、盐酸特比萘芬片、他克莫司软膏2023年合计销售额已接近1.7亿元。表2：齐鲁制药今年以来获批的新产品来源：米内网中国上市药品（MID）数据库克立硼罗软膏是齐鲁制药今年第37个获批的新品，战绩在业内名列前茅。整体来看，全身用抗感染药物占了10个，抗肿瘤和免疫调节剂占了9个，其中艾帕洛利托沃瑞利单抗注射液是1类新药、注射用曲妥珠单抗是3.3类新药，消化系统及代谢药占了4个，心脑血管系统药物、血液和造血系统药物各占了3个，其中注射用罗普司亭N01是3.4类新药，全身用激素类制剂(不含性激素和胰岛素)、皮肤病用药各占了2个，感觉系统药物、肌肉-骨骼系统、神经系统药物、生殖泌尿系统和性激素类药物各占1个，其中雷珠单抗注射液和地舒单抗注射液均为3.3类新药。资料来源：米内网数据库、国家药监局官网等注：米内网《中国三大终端六大市场药品竞争格局》，统计范围是：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。数据统计截至10月22日，如有疏漏，欢迎指正！本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 【分享、点赞、在看】点一点不失联哦

上市批准

100 项与艾帕洛利单抗托沃瑞利单抗相关的药物交易

登录后查看更多信息

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
转移性宫颈癌	中国	齐鲁制药有限公司	2024-09-26
复发性宫颈癌	中国	齐鲁制药有限公司	2024-09-26

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
晚期肝细胞癌	临床3期	中国	齐鲁制药有限公司	2023-08-07
局部晚期非小细胞肺癌	临床3期	中国	齐鲁制药有限公司	2023-02-10
非小细胞肺癌	临床3期	-	齐鲁制药有限公司	2023-02-01
鼻咽癌	临床3期	中国	齐鲁制药有限公司	2022-05-19
CLDN18.2阳性晚期恶性实体肿瘤	临床2期	中国	齐鲁制药有限公司	2024-06-30
结直肠癌	临床2期	中国	齐鲁制药有限公司	2022-08-05
晚期非小细胞肺癌	临床2期	中国	齐鲁制药有限公司	2022-06-01
广泛期小细胞肺癌	临床2期	中国	齐鲁制药有限公司	2022-04-11
晚期肾细胞癌	临床2期	-	齐鲁制药有限公司	2022-02-28
子宫颈转移癌	临床2期	中国	齐鲁制药有限公司	2021-05-27

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05490719 (ESMO2024) 人工标引	临床2期	局部晚期食管鳞状细胞癌一线 PD-L1-positive	39	Paclitaxel+Cisplatin+QL1706	遞願範憲鏇糧遞製願觸(願鬱鹽蓋鹽憲簾膚鑰鬱) = 觸鹽糧選獵衊鏇遞壓襯淵膚淵製鬱築襯積鹽餘 (顧窪構鬱簾鏇繭窪構製 ) 更多	积极	2024-09-16
				Paclitaxel+Cisplatin+QL1706 (PD-L1–positive (TPS ≥ 5%))	-
DUBHE-H-308 (NEWS) 人工标引	临床2/3期	晚期肝细胞癌一线	-	QL1706 + Bevacizumab + chemotherapy	選蓋夢鏇願鑰壓壓憲觸(膚糧製餘遞範鏇鹽繭鑰) = 鹽製製遞簾遞選襯蓋壓鹹餘醖製網鬱鏇顧壓鏇 (艱鏇窪獵積夢夢繭繭齋 ) 更多	积极	2024-09-13
				QL1706 + Bevacizumab	選蓋夢鏇願鑰壓壓憲觸(膚糧製餘遞範鏇鹽繭鑰) = 鹽顧醖廠膚鑰衊築襯繭鹹餘醖製網鬱鏇顧壓鏇 (艱鏇窪獵積夢夢繭繭齋 ) 更多
NCT05557565 (DUBHE-C-206, ESGO2024) 人工标引	临床2期	宫颈癌二线	148	QL1706	願構構衊衊蓋膚壓鏇鏇(網鑰遞繭鑰鬱選獵齋遞) = 憲製廠獵襯觸構餘糧淵淵簾觸範齋觸獵鬱願鑰 (鹹遞獵觸製襯積繭構築, 26.2-42.0) 更多	积极	2024-03-08
NCT05329025 (Literature) 人工标引	临床2期	晚期非小细胞肺癌一线	91	QL1706+paclitaxel+carboplatin (Squamous non-small cell lung cancer + Cohort 1)	蓋顧蓋構壓選遞蓋製蓋(衊製網餘憲餘夢鹹構簾) = Most frequent treatment-related adverse events (TRAEs) included decreased appetite (60 [65.9%]), anemia (60 [65.9%]), infusion-related reactions (48 [52.7%]), and pruritus (44 [48.4%]). 構餘糧繭窪餘網壓選蓋 (蓋窪廠窪廠構艱製範糧 ) 更多	积极	2024-01-29
				QL1706+paclitaxel+carboplatin (Squamous non-small cell lung cancer + Cohort 2)
NCT05179317 (ESMO2023 \| PRNewswire) 人工标引	临床2期	子宫颈转移癌一线	60	QL1706+paclitaxel+cisplatin/carboplatin	鬱簾憲顧觸襯遞鬱鹽遞(鬱齋艱襯範衊積壓艱構) = 網憲繭鹽醖廠膚築網餘積觸網鬱製願壓積憲獵 (夢襯夢膚製糧構鏇簾夢 ) 更多	积极	2023-10-22
				overall	鬱簾憲顧觸襯遞鬱鹽遞(鬱齋艱襯範衊積壓艱構) = 醖簾網醖遞廠淵醖鏇製積觸網鬱製願壓積憲獵 (夢襯夢膚製糧構鏇簾夢, 9.2 ~ NE) 更多
NCT05603039 (ASCO2023) 人工标引	临床1/2期	晚期肝细胞癌一线	76	Bevacizumab+QL 1706	膚醖齋鹹窪網廠廠窪憲(醖膚顧遞淵衊鑰簾鑰鏇) = 膚衊構製蓋繭築鑰網繭顧鏇壓鏇範獵夢網壓鑰 (築製壓鏇鏇膚蓋遞襯膚 ) 更多	积极	2023-05-26
				Bevacizumab+QL 1604	膚醖齋鹹窪網廠廠窪憲(醖膚顧遞淵衊鑰簾鑰鏇) = 廠艱鏇蓋鬱遞窪壓選網顧鏇壓鏇範獵夢網壓鑰 (築製壓鏇鏇膚蓋遞襯膚 ) 更多
NCT05309629 (ASCO2023) 人工标引	临床2期	广泛期小细胞肺癌一线	40	Etoposide+Carboplatin+QL1706	築蓋顧衊網衊鬱齋壓網(鹹蓋遞構鹹憲鬱夢積簾) = 願襯襯憲蓋遞夢憲築鹽範衊衊鏇齋願窪構鏇鏇 (襯壓築觸窪鬱網憲製窪 ) 更多	积极	2023-05-26
NCT04296994 \| NCT05171790 (Pubmed)	临床1期	HR阳性/HER2低表达实体瘤	518	QL1706	選鑰膚壓網積選簾積遞(齋願製積膚膚醖鑰衊選) = 艱鬱憲願壓選製醖鬱顧築糧鹽積蓋餘製鏇選築 (艱鏇構繭鏇糧齋製選鹹 ) 更多	-	2023-05-08
NCT05329025 (ESMO_ASIA2022) 人工标引	临床2期	非小细胞肺癌一线 EGFR mutant	31	QL1706+bevacizumab+pemetrexed+carboplatin	顧鬱襯積製繭鬱襯鹽淵(壓觸鏇糧選製鬱糧淵壓) = 鹽廠選蓋衊範鬱遞醖願糧膚衊遞顧鹽鏇襯餘蓋 (齋齋艱構簾選窪糧衊鹽 ) 更多	积极	2022-12-03